The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000–2009

Frank Lichtenberg

Economics & Human Biology, 2014, vol. 13, issue C, 107-127

Abstract: Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at death) and medical expenditure in France during the period 2000–2009. The estimates imply that pharmaceutical innovation increased mean age at death by 0.29 years (3.43 months) during this period—about one-fifth of the total increase in longevity. This estimate is smaller than those obtained in previous studies of Germany and the U.S., but the rate of adoption of new drugs was lower in France. Longevity is much more strongly related to the number of drugs than it is to the number of drug classes.

Keywords: Longevity; Life expectancy; Pharmaceutical; Innovation; Hospital; Health care expenditure (search for similar items in EconPapers)
Date: 2014
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (7)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S1570677X13000373
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:ehbiol:v:13:y:2014:i:c:p:107-127

DOI: 10.1016/j.ehb.2013.04.002

Access Statistics for this article

Economics & Human Biology is currently edited by J. Komlos, Inas R Kelly and Joerg Baten

More articles in Economics & Human Biology from Elsevier
Bibliographic data for series maintained by Catherine Liu ().